Unity Biotechnology, Inc. (UBX) |
|
0.405 -0.027 (-6.32%)
|
09-24 16:06 |
|
Open: |
0.41 |
Pre. Close: |
0.4323 |
|
High:
|
0.425 |
Low:
|
0.39 |
|
Volume:
|
1,275,814 |
Market Cap:
|
57(M) |
|
|
|
|
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.43 - 0.43 |
0.43 - 0.43 |
|
Low:
|
0.38 - 0.39 |
0.39 - 0.39 |
|
Close:
|
0.4 - 0.41 |
0.41 - 0.41 |
|
Technical analysis |
as of: 2022-09-23 4:28:10 PM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 0.65  One year: 0.77 |
| Support: |
Support1: 0.38 Support2: 0.32 |
| Resistance: |
Resistance1: 0.55 Resistance2: 0.66 |
| Pivot: |
0.46 |
| Moving Average: |
MA(5): 0.43 MA(20): 0.46
MA(100): 0.67 MA(250): 1.2 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1  |
| Stochastic oscillator: |
%K(14,3): 11.1 %D(3): 15.6 |
| RSI: |
RSI(14): 35.4 |
| 52-week: |
High: 3.64 Low: 0.38 |
| Average Vol(K): |
3-Month: 4,071 (K) 10-Days: 1,160 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ UBX ] has closed above bottom band by 3.8%. Bollinger Bands are 62.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Thu, 22 Sep 2022
What is Unity Biotechnology Inc. (UBX) Stock Return on Shareholders' Capital? - SETE News
Mon, 19 Sep 2022
The Three Best Anti-Aging Stocks to Buy in September - InvestorPlace
Tue, 13 Sep 2022
Views of Wall Street's Leading Experts on Unity Biotechnology Inc. - SETE News
Mon, 12 Sep 2022
UBX wants to change how you go to the gym through boxing - Business Plus
Mon, 05 Sep 2022
UBX, SouthBank partner to beef up digital rural banking in Mindanao - The Manila Times
Wed, 31 Aug 2022
UNITY Biotechnology to Participate in Upcoming Investor Conferences - Unity Biotechnology (NASDAQ:UBX) - Benzinga
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
134 (M) |
|
% Held by Insiders
|
6.337e+007 (%) |
|
% Held by Institutions
|
2.6 (%) |
|
Shares Short
|
361 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-5.074e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-1 |
|
Return on Assets (ttm)
|
62.7 |
|
Return on Equity (ttm)
|
-28.6 |
|
Qtrly Rev. Growth
|
5.02e+006 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
-174.77 |
|
EBITDA (p.s.)
|
-5.25156e+007 |
|
Qtrly Earnings Growth
|
-1.1 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-46 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.01 |
|
Price to Cash Flow
|
0.45 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
350630 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
